These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35583138)

  • 1. Mammographic Density Decline, Tamoxifen Response, and Prognosis by Molecular Characteristics of Estrogen Receptor-Positive Breast Cancer.
    Abubakar M; Mullooly M; Nyante S; Pfeiffer RM; Aiello Bowles EJ; Cora R; Bodelon C; Butler E; Butcher D; Sternberg L; Troester MA; Weinmann S; Sherman M; Glass AG; Berrington de Gonzalez A; Gierach GL
    JNCI Cancer Spectr; 2022 May; 6(3):. PubMed ID: 35583138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
    Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
    Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between mammographic density and basal-like and luminal A breast cancer subtypes.
    Razzaghi H; Troester MA; Gierach GL; Olshan AF; Yankaskas BC; Millikan RC
    Breast Cancer Res; 2013; 15(5):R76. PubMed ID: 24008056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer.
    Nyante SJ; Sherman ME; Pfeiffer RM; Berrington de Gonzalez A; Brinton LA; Aiello Bowles EJ; Hoover RN; Glass A; Gierach GL
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25663687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
    Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
    JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
    Cheang MC; Chia SK; Voduc D; Gao D; Leung S; Snider J; Watson M; Davies S; Bernard PS; Parker JS; Perou CM; Ellis MJ; Nielsen TO
    J Natl Cancer Inst; 2009 May; 101(10):736-50. PubMed ID: 19436038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer.
    Bjerre C; Knoop A; Bjerre K; Larsen MS; Henriksen KL; Lyng MB; Ditzel HJ; Rasmussen BB; Brünner N; Ejlertsen B; Laenkholm AV
    Acta Oncol; 2013 Jan; 52(1):82-90. PubMed ID: 23205744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical value of progesterone receptor expression in luminal breast cancer: A study of a large cohort with long-term follow-up.
    Lashen AG; Toss MS; Mongan NP; Green AR; Rakha EA
    Cancer; 2023 Apr; 129(8):1183-1194. PubMed ID: 36653923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ano1/TMEM16A Overexpression Is Associated with Good Prognosis in PR-Positive or HER2-Negative Breast Cancer Patients following Tamoxifen Treatment.
    Wu H; Guan S; Sun M; Yu Z; Zhao L; He M; Zhao H; Yao W; Wang E; Jin F; Xiao Q; Wei M
    PLoS One; 2015; 10(5):e0126128. PubMed ID: 25961581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline breast tissue characteristics determine the effect of tamoxifen on mammographic density change.
    Gabrielson M; Hammarström M; Bergqvist J; Lång K; Rosendahl AH; Borgquist S; Hellgren R; Czene K; Hall P
    Int J Cancer; 2024 Jul; 155(2):339-351. PubMed ID: 38554131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer.
    Abubakar M; Figueroa J; Ali HR; Blows F; Lissowska J; Caldas C; Easton DF; Sherman ME; Garcia-Closas M; Dowsett M; Pharoah PD
    Mod Pathol; 2019 Sep; 32(9):1244-1256. PubMed ID: 30976105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between mammographic density and tumor marker-defined breast cancer subtypes: a case-control study.
    Shin J; Lee JE; Ko HY; Nguyen TL; Nam SJ; Hopper JL; Song YM
    Eur J Cancer Prev; 2018 May; 27(3):239-247. PubMed ID: 28957821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
    Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
    Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.
    Van Asten K; Slembrouck L; Olbrecht S; Jongen L; Brouckaert O; Wildiers H; Floris G; Van Limbergen E; Weltens C; Smeets A; Paridaens R; Giobbie-Hurder A; Regan MM; Viale G; Thürlimann B; Vergote I; Christodoulou E; Van Calster B; Neven P
    Oncologist; 2019 Feb; 24(2):165-171. PubMed ID: 30171067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information.
    Feeley LP; Mulligan AM; Pinnaduwage D; Bull SB; Andrulis IL
    Mod Pathol; 2014 Apr; 27(4):554-61. PubMed ID: 24051696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.